Findings

What do systematic reviews say?

45 questions · 45 findings · 4 reviews

No studies found 14 · 31.1%GRADE not reported 0 · 0%Very low 12 · 26.7%Low 6 · 13.3%Moderate 3 · 6.7%High 10 · 22.2%

Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1103 participants
High

Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( · type 2 diabetes mellitus

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1109 participants
High

Adverse events ‐ All‐cause infections ( · type 2 diabetes mellitus

The intervention leads to higher adverse events ‐ All‐cause infections ( (high certainty).

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
RR 1.29 [1.09, 1.52]
8 studies · 3589 participants
High

Morbidity · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Health‐related quality of life · patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus 2008 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found